Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-09
2010-11-16
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S322500, C548S324100
Reexamination Certificate
active
07834043
ABSTRACT:
A compound of the formulais disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
REFERENCES:
patent: 4221789 (1980-09-01), Rodriguez et al.
patent: 5142056 (1992-08-01), Kempf et al.
patent: 5294720 (1994-03-01), Jadhav et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 5541206 (1996-07-01), Kempf et al.
patent: 5712417 (1998-01-01), Budt et al.
patent: 5914332 (1999-06-01), Sham et al.
patent: 6204257 (2001-03-01), Stella et al.
patent: 6559137 (2003-05-01), Tung et al.
patent: 0 005 689 (1979-11-01), None
patent: 0 342 541 (1989-11-01), None
patent: 0 365 992 (1990-05-01), None
patent: 0 428 849 (1991-05-01), None
patent: 0 580 402 (1994-01-01), None
patent: 0 346 847 (1994-05-01), None
patent: 0 604 910 (1994-07-01), None
patent: 89/10752 (1989-11-01), None
patent: 93/07128 (1993-04-01), None
patent: 94/14436 (1994-07-01), None
patent: 97/19061 (1997-05-01), None
patent: 00/40558 (2000-07-01), None
Spina et al, Curr Opin Oncol, Sep. 2005, 17(5), abstract.
Y. Becker, et al.,Asymmetric Hydroformylation and Hydrocarboxylation of Enamides. Synthesis of Alanine and Proline, J. Org. Chem., vol. 45, pp. 2145-2151 (1980).
Ghosh, et al., “Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir”, Chem. Commun., pp. 1025-1026 (1999).
J. Golik, “Synthesis and Antitumor Evaluation of Paclitaxel Phosphonooxymethyl Ethers: A Novel Class of Water Soluble Paclitaxel Pro-Drugs”, Bioorg. Med. Chem. Lett, vol. 6, pp. 1837-1842 (1996).
Jindrich, J., et al., Synthesis of N-(3-Fluoro-2-Phosphonomethoxypropyl) (FPMP) Derivates of Heterocyclic Bases, Collect Czech. Chem. Commun., vol. 58 (7), pp. 1645-1667 (1993).
R. Randad, et al., “De Novo Design of NonPeptidic HIV-1 Protease Inhibotors: Incorporation of Structural Water”, Bioorg. Med. Chem. Lett., vol. 4, No. 10, pp. 1247-1252 (1994).
Scholz, D. et al., “Inhibitors of HIV-1 Proteinase Containing 2-Heterosubstituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Enzyme Inhibition, and Antiviral Activity”, J. of Med. Chem., vol. 37, pp. 3079-3089 (1994).
A. Smith, et al., “Pyrrolinone-Based HIV Protesase Inhibotrs. Design, Synthesis, and Antiviral Activity: Evidence for Improved Transport”, J. Am. Chem. Soc., vol. 117, pp. 11113-11123 (1995).
H. Takechi, et al., Photoreactions of Succinimides with an N-Acyl Group in the Side Chain. Synthesis and Stereochemistry of Tricyclic Pyrrolo [1,2-a]pyrazine Ring Systems1)Chem. Pharm. Bull., vol. 34, No. 8, pp. 3142-3152 (1986).
J. Vacca, et al., “Conformationally Constrained HIV-1 Protease Inhibitors”, Bioorg. Med. Chem. Letts., vol. 4, No. 3, pp. 499-504 (1994).
Ettmayer, P., et al., “Novel, Extended Transition State Mimic in HIV-I Protease Inhibitors with Peripheral C2-Symmetry”,Biorganic&Med. Chem. Ltrs., 4(24):2851-2856 (1994).
Kempf, D.J., et al., “Antiviral and Pharmacokinetic Properties of C2Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease”,Antimicrobial Agents and Chemotherapy, 2209-2214 (1991).
Nillroth, U., et al., “Human Immunodeficiency Virus Type 1 Proteinase Resistance to Symmetric Cyclic urea Inhibitor Analogs”,Antimicrobial Agents&Chemotherapy, 2383-2388 (1997).
Tossi, A., et al., “Aspartic protease inhibitors”,Eur. J. Biochem., 267:1715-1722 (2000).
DeGoey David A.
Flentge Charles A.
Flosi William J.
Grampovnik David J.
Kempf Dale J.
Abbott Laboratories
Andres Janet L
Gallis David E
Zhang Xu
LandOfFree
HIV protease inhibiting compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV protease inhibiting compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV protease inhibiting compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251317